Loading
EB
Evelo Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Jul 2023.
Evelo Biosciences, Inc.: what insiders have been doing
Evelo Biosciences, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Evelo Biosciences, Inc. The previous disclosure was published on 8 November 2023.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
41
Thresholds
n/a
Buy Volume
n/a
5 ops. · all time
Sell Volume
€404
5 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.00
Analyst consensus
Income statement
EBITDA-US$106.9M
Net income-US$114.5M0.0% margin
Valuation
Beta-25.24
Balance sheet & cash
Market capUS$1.9k
Total debtUS$51.1M
Free Cash Flow-US$101.9M
Profitability & ownership
ROA-83.2%
% insiders0.0%
% institutions0.0%
Last declaration on 8 November 2023
Declarations41 total
6,500 sharesCommon StockSEC:0001694665-23-000178:0
6,500 sharesCommon StockSEC:0001694665-23-000175:0
6,625 sharesCommon StockSEC:0001694665-23-000179:0
1,172 sharesCommon StockSEC:0001694665-23-000176:0
12,500 sharesCommon StockSEC:0001694665-23-000169:0
12,500 sharesCommon StockSEC:0001694665-23-000167:0
12,500 sharesCommon StockSEC:0001694665-23-000168:0
15,000 sharesCommon StockSEC:0001694665-23-000160:0
1,171 sharesCommon StockSEC:0001694665-23-000135:0
6,500 sharesCommon StockSEC:0001694665-23-000133:0
6,500 sharesCommon StockSEC:0001694665-23-000134:0
6,625 sharesCommon StockSEC:0001694665-23-000136:0
1,082,251 shares@ €2.097327.6% of flowCommon StockSEC:0000950170-23-032871:0
Canonical exit: 9 Oct 2023 (T+90)
22,571 shares@ €0.131727.7% of flowCommon StockSEC:0001694665-23-000080:0
38,531 shares@ €0.1141100.0% of flowCommon StockSEC:0001694665-23-000052:0
68,014 shares@ €0.114172.3% of flowCommon StockSEC:0001694665-23-000053:0
66,730 shares@ €0.114114.1% of flowCommon StockSEC:0001694665-23-000054:0
3,537 shares@ US$0.1255100.0% of flowCommon StockSEC:0001694665-23-000051:0
23,437 sharesCommon StockSEC:0001694665-23-000043:0
130,000 sharesCommon StockSEC:0001694665-23-000041:0
130,000 sharesCommon StockSEC:0001694665-23-000044:0
132,500 sharesCommon StockSEC:0001694665-23-000042:0
1,250 shares@ US$0.888.3% of flowCommon StockSEC:0001694665-23-000004:0
354 sharesCommon StockSEC:0001694665-23-000002:0
1,250 shares@ €1.756218.0% of flowCommon StockSEC:0001694665-22-000132:0
25 of 41 declarations
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a United States biopharmaceutical company that was listed on NASDAQ, and its corporate history is best understood through the lens of development-stage biotech risk. The company was incorporated in Delaware in 2014 and was headquartered in Cambridge, Massachusetts, a major U.S. life-sciences cluster. Evelo built its identity around a novel scientific thesis: developing “monoclonal microbial” therapies designed to engage immune cells in the small intestine and trigger systemic immune effects across the body. In its filings, the company described this as the “gut-body network,” initially targeting inflammatory diseases and cancer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1694665/000169466519000013/evelo10-k.htm?utm_source=openai))
From an equity analyst’s perspective, Evelo was not a diversified commercial biotech with a broad product franchise. It was a research-driven platform company with substantial dependence on external capital, clinical progress, and regulatory execution. Its core work centered on microbial therapeutics rather than marketed drugs, which meant that the upside case relied on scientific validation and successful development milestones, while the downside reflected the usual small-cap biotech risks: financing needs, competition from larger and better-capitalized peers, and the possibility of never reaching profitability. The company’s SEC disclosures explicitly noted that it had not generated revenue from its primary business purpose. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1694665/000169466519000013/evelo10-k.htm?utm_source=openai))
Read moreShow less
A major recent development reshaped the investment case. In January 2024, Evelo filed materials with the SEC for a special stockholder meeting that included approval of a plan of liquidation and dissolution. That filing is highly significant because it indicates that the company moved away from a conventional growth-and-commercialization path and toward winding down operations and liquidating assets. For investors, this changes the interpretation of the name entirely: EVLO is no longer a typical pipeline story, but a liquidation/special-situation profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1694665/000114036123057273/edge20015072x3_def14a.htm?utm_source=openai))
Geographically, the business was overwhelmingly U.S.-based, with principal offices in Cambridge, Massachusetts. The company’s scientific positioning also benefited from academic and research ties in the United States, including licensed intellectual property referenced in earlier SEC materials. However, scientific differentiation did not translate into a durable commercial footprint, and the market position remained that of a niche, highly speculative micro-cap biotech rather than a scaled pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1694665/000169466519000013/evelo10-k.htm?utm_source=openai))
For French, Belgian, and Swiss investors, the key takeaway is straightforward: Evelo Biosciences was a NASDAQ-listed U.S. biotechnology company built on an innovative immunology/microbiome concept, but the most important recent event was the decision to liquidate and dissolve the business. In practical terms, any analysis of EVLO should be framed around capital return, asset realization, and residual risk rather than around future product commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1694665/000114036123057273/edge20015072x3_def14a.htm?utm_source=openai))
